Education
About Us
Working with TipRanks
Follow Us
Delcath Systems (DCTH)
NASDAQ:DCTH
DCTH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.26 - $16.97
Previous CloseN/A
Volume96.76K
Average Volume (3M)413.82K
Market Cap
$476.33M
Enterprise Value$281.16M
Total Cash (Recent Filing)$32.41M
Total Debt (Recent Filing)$1.04M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
May 13, 2025EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.98
Shares Outstanding33,403,137
10 Day Avg. Volume462,807
30 Day Avg. Volume413,818
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)12.32
Price to Cash Flow (P/CF)-114.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.06
Enterprise Value/Ebitda-18.59
Forecast
1Y Price Target
$22.00Price Target Upside64.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Delcath Systems News
PremiumCompany Announcements
Delcath Systems Braces for Financial Impact Amid Uncertain Tax Law ChangesPremiumCompany Announcements
Delcath Systems Reports Strong 2024 Financial Growth
PremiumPre-Earnings
Is DCTH a Buy, Before Earnings?---
Bulls Say, Bears Say
Bulls Say
Investment OpportunityDelcath presents a rare investment opportunity in biotech: growing revenues, profitability, and soon to be cash flow positive.
Market ExpansionContinued revenue growth is expected, driven by new site activation.
Revenue PerformanceHepzato revenue beat with $13.7M vs. $11.7M consensus.
Bears Say
Risks And ChallengesRisks associated with Delcath include commercial, clinical, regulatory, and competition challenges.
---
Ownership Overview
28.92% Insiders
4.34% Mutual Funds
27.97% Other Institutional Investors
34.47% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
DCTH FAQ
What was Delcath Systems’s price range in the past 12 months?
Delcath Systems lowest stock price was $4.26 and its highest was $16.97 in the past 12 months.
What is Delcath Systems’s market cap?
Delcath Systems’s market cap is $476.33M.
When is Delcath Systems’s upcoming earnings report date?
Delcath Systems’s upcoming earnings report date is May 13, 2025 which is in 46 days.
How were Delcath Systems’s earnings last quarter?
Delcath Systems released its earnings results on Mar 06, 2025. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.001 by -$0.109.
Is Delcath Systems overvalued?
According to Wall Street analysts Delcath Systems’s price is currently Undervalued.
Does Delcath Systems pay dividends?
Delcath Systems does not currently pay dividends.
What is Delcath Systems’s EPS estimate?
Delcath Systems’s EPS estimate is 0.02.
How many shares outstanding does Delcath Systems have?
Delcath Systems has 33,403,137 shares outstanding.
What happened to Delcath Systems’s price movement after its last earnings report?
Delcath Systems reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.001. Following the earnings report the stock price went down -1.564%.
Which hedge fund is a major shareholder of Delcath Systems?
Currently, no hedge funds are holding shares in DCTH
---
Delcath Systems Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.00 (64.18% Upside)
$22.00 (64.18% Upside)
Blogger Sentiment
Bullish
DCTH Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 697.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.7%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
189.15%
12-Months-Change
Fundamentals
Return on Equity
-62.43%
Trailing 12-Months
Asset Growth
98.35%
Trailing 12-Months
Company Description
Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
---
DCTH Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance in the U.S. market with the launch of HEPZATO and significant growth in Europe, despite challenges with pricing and high operational expenses. The company's strategic focus on expanding treatment centers and R&D initiatives suggests a positive outlook.Read More>---
DCTH Stock 12 Month Forecast
Average Price Target
$22.00
▲(64.18% Upside)
Technical Analysis
Best Analysts Covering DCTH
1 Year
1 Year Success Rate
12/14 ratings generated profit
1 Year Average Return
+48.71%
reiterated a buy rating 22 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +48.71% per trade.
---